BioMaxima S.A.

BMX

PLBIOMX00015

Pharmaceuticals

Delayed Warsaw S.E. Other stock markets 04:56:38 24/05/2024 pm IST			5-day change	1st Jan Change
13.95 ^PLN	+0.72%		-1.06%	-15.04%

2023	BioMaxima S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI
2023	BioMaxima S.A. Reports Earnings Results for the Half Year Ended June 30, 2023	CI

BioMaxima Spolka Akcyjna signed an agreement to acquire BIOCORP Polska sp. z o.o.

August 04, 2016

BioMaxima Spolka Akcyjna (WSE:BMX) signed an agreement to acquire BIOCORP Polska sp. z o.o. on August 4, 2016. Shareholders of BIOCORP Polska will receive 0.69 million shares of BioMaxima for 100% of their shares in BIOCORP Polska. Current partners of BIOCORP Polska will receive additional payment of PLN 0.2 per share to each share of BioMaxima received.

Latest news about BioMaxima S.A.

BioMaxima S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	29/11	CI
BioMaxima S.A. Reports Earnings Results for the Half Year Ended June 30, 2023	29/23/29	CI
BioMaxima S.A. Reports Earnings Results for the First Quarter Ended March 31, 2023	30/23/30	CI
BioMaxima S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	28/22/28	CI
BioMaxima S.A. Reports Earnings Results for the Half Year Ended June 30, 2022	30/22/30	CI
BioMaxima S.A. Reports Earnings Results for the First Quarter Ended March 31, 2022	30/22/30	CI
BioMaxima S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	20/21/20	CI
BioMaxima S.A. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2021	16/21/16	CI
Biomaxima S.A. Reports Earnings Results for the Fourth Quarter Ended December 31, 2020	16/21/16	CI
Biomaxima S.A. Reports Earnings Results for the Second Quarter Ended June 30, 2020	29/20/29	CI
BioMaxima Enters into Agreement with Pure Biologics	23/17/23	CI
BioMaxima Spolka Akcyjna completed the acquisition of BIOCORP Polska sp. z o.o.	20/16/20	CI
BioMaxima Spolka Akcyjna signed an agreement to acquire BIOCORP Polska sp. z o.o.	04/16/04	CI
Bioavlee Sp. z o.o announced that it has received PLN 0.2 million in funding from BioMaxima Spolka Akcyjna.	05/15/05	CI
BioMaxima Spolka Akcyjna completed the acquisition of CEBO Sp. z o.o. from Benedykt Cebo and Elwira Cebo.	20/14/20	CI
BioMaxima Spolka Akcyjna signed a preliminary agreement to acquire CEBO Sp. z o.o. from Benedykt Cebo and Elwira Cebo for PLN 0.38 million.	25/13/25	CI
BioMaxima Spolka Akcyjna (WSE: BMX) completed the acquisition of Emapol Sp.z.o.o.	27/12/27	CI
BioMaxima Spolka Akcyjna announced that it has received PLN 7.50 million in funding from Emapol Sp.z.o.o. and other investors.	14/12/14	CI

Chart BioMaxima S.A.

Duration

Period

More charts

Company Profile

BioMaxima SA is a Poland-based company active in the laboratory diagnostics sector. It manufactures and distributes reagents and equipment for the laboratory diagnosis. It produces reagents for the in vitro diagnosis. The main product groups offered by BioMaxima include: diagnostic reagents and analyzers for clinical biochemistry; rapid tests and readers for detecting infectious diseases, cancer markers, cardiac markers and drugs of abuse; urine analysis systems; hematology analyzers and reagents; ion-selective analyzers and reagents; reagents and immunological analyzers of cardiac markers; glucometers; analyzers for gasometric tests and critical blood parameters tests. The Company supplies hospitals and laboratories in Poland, as well as in Lithuania, Latvia, Romania and France. On March 20, 2014, the Company merged with its wholly owned subsidiary Cebo Sp z o o.

Sector

Pharmaceuticals

More about the company